Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

BeiGene Announces Approval of PARP Inhibitor in China

publication date: May 7, 2021

BeiGene, a Beijing biotech, announced China granted conditional approval for its PARP inhibitor, the company's third China approval. Pamiparib was approved as a third-line treatment for recurrent advanced ovarian, fallopian tube or primary peritoneal cancer with germline BRCA mutations. BeiGene said pamiparib is currently being tested in multiple global trials, including seven China trials for solid tumor malignancies. BeiGene plans a China launch for the PARP inhibitor this month. More details....

Stock Symbols: (NSDQ: BGNE; HK: 06160)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital